New Antimalarial: Tafenoquine

Tafenoquine has been approved by the Food and Drug Administration (FDA) for prophylaxis of malaria in adults (Arakoda^TM, 60 Degrees Pharmaceutical, 100 mg tablets) and for radical cure of Plasmodium vivax in persons greater than 16 years old (Krintafel^TM, GSK, 150 mg tablets). Tafenoquine is only the second drug of its kind to receive FDA approval. Prior to using these drugs, patients must be tested and found to have normal glucose-6-phosphate dehydrogenase activity. More information is available at  https://academic.oup.com/jtm/article/25/1/tay071/5076819.

More on: Treatment of Malaria in the United States

More on: Choosing a Drug to Prevent Malaria